FARROW & BALL LIMITED

Financial Health Score: B+ (Conditional)

Explanation: Based on the administrative and structural data available, Farrow & Ball Limited exhibits strong signs of corporate vitality and compliance. However, a definitive A-grade cannot be awarded without the quantitative "blood work"—specifically, the turnover, assets, and profitability figures which are missing from this dataset. The grade reflects a healthy, long-standing patient that is well-managed but requires a full financial blood panel to confirm peak condition.

1. Key Vital Signs

• Corporate Longevity (Incorporation Date): 1971. This patient is over 50 years old. In business terms, surviving multiple economic cycles indicates a robust constitutional foundation and a highly resilient business model.
• Regulatory Pulse (Filing Compliance): Healthy. The company’s accounts and confirmation statements are up to date, with the next accounts not due until September 2027. There are no overdue filings, meaning the company is breathing steadily and complying with its statutory obligations.
• Transparency & Scale (Accounts Category & SIC Codes): Full. The company files "Full" accounts rather than abbreviated or micro-accounts, indicating it exceeds the small company thresholds. The SIC codes (Manufacture of wallpaper and paints/varnishes) confirm its core manufacturing operations as a premium heritage brand.
• Corporate DNA (PSC & Ownership): Wholly Owned Subsidiary. Farrow & Ball Holdings Limited owns more than 75% of shares and voting rights. This is a common structure for established brands, providing access to group-level financial support, though it also means the patient's vital signs are intrinsically linked to the parent company's health.
• Share Capital: £94,155. A relatively modest issued share capital, which typically suggests that the company’s growth and operations have been funded through retained profits (a healthy sign) or intercompany group loans rather than constant capital injections.

2. Symptoms Analysis

• Boardroom Circulation (Recent Resignations): There has been a recent change in the board's composition with the resignation of Director Mira Gvozdenovic in December 2025. While a single director resignation is rarely a symptom of a critical condition, it is a mild symptom that warrants observation. It could indicate a healthy restructuring, a change in group-level strategy, or simply natural career progression.
• International Blood Flow (Officer Demographics): The current board includes officers of Portuguese and Danish nationality, alongside a dedicated CEO. For a UK-based premium manufacturer, an international leadership team is a highly positive symptom. It suggests the company has a global outlook and is exporting its brand effectively, bringing healthy international revenue into the UK bloodstream.
• Missing Blood Work (Financial Metrics): The most notable symptom in this assessment is the absence of quantitative financial data (turnover, net assets, current liabilities). Without these, we cannot measure the company's cash flow rhythm, profitability, or liquidity. We are forced to assess the patient's health purely by observing their outward appearance and habits rather than their internal physiology.

3. Diagnosis

Diagnosis: Structurally Sound, Clinically Obscured

Farrow & Ball Limited is an active, well-established private limited company that demonstrates excellent administrative health. Its longevity as a manufacturer of premium paints and wallpapers, combined with its status as a wholly-owned subsidiary of a holding company, suggests it is a carefully managed asset. The transition from its original name in 1992 marks a successful historical evolution.

However, because the quantitative financial data (the "blood test" results) is not present in this examination, a complete internal diagnosis is restricted. We can see that the patient is up and walking, compliant with the law, and supported by a broader corporate group, but we cannot definitively rule out underlying financial strain, such as over-leverage through intercompany debt or thin working capital margins, without viewing the full balance sheet.

4. Recommendations

To ensure long-term financial wellness and achieve a clean bill of health, the following actions are recommended:

1. Conduct a Full Financial Blood Panel: Request and review the full, filed annual accounts at Companies House. Specifically, examine the net current assets (working capital) to ensure the company can pay its short-term debts, and review the P&L reserve to confirm that the business is retaining profits rather than bleeding cash.
2. Monitor the Group's Vital Signs: Because Farrow & Ball Limited is controlled by Farrow & Ball Holdings Limited, the subsidiary's health is heavily influenced by the parent. Review the holding company's accounts to ensure there are no contagious financial illnesses (such as group-wide debt covenants or cash flow restrictions) that could impact the operating company.
3. Post-Operative Review on Board Changes: Conduct a brief internal review regarding the recent director resignation (December 2025). Ensure that all operational responsibilities have been smoothly transitioned and that the change does not signal any underlying strategic disagreements or disruptions in the management pipeline.